ApoB vs LDL: The Cholesterol Test Your Doctor Probably Isn't Ordering

For decades, LDL cholesterol — the so-called "bad cholesterol" — has been the standard measure of cardiovascular risk. If your LDL was in range, you were considered low-risk. Millions of heart attacks happened to people with "normal" LDL.

The problem is that LDL measures cholesterol mass, not the particles that carry it. And it is the particles — specifically, their number and density — that drive arterial damage.

Why ApoB is the superior marker

ApoB (apolipoprotein B) is a protein that sits on the surface of every atherogenic lipoprotein particle — every LDL, VLDL, IDL, and Lp(a) molecule that can penetrate your arterial walls. One ApoB = one particle. This makes it a direct count of cardiovascular threat.

A landmark 2022 European Heart Journal study showed that ApoB predicted MACE (major adverse cardiovascular events) with significantly greater accuracy than LDL-C across all age groups and metabolic profiles. The European Society of Cardiology now recommends ApoB as a primary cardiovascular risk marker.

The dangerous gap: normal LDL, high ApoB

This is the critical scenario. A person can have a "normal" LDL reading — say, 3.2 mmol/L — while carrying a very high number of small, dense LDL particles (sdLDL). These particles are smaller, penetrate arterial walls more easily, and are more susceptible to oxidation. Their total cholesterol mass may appear normal, but ApoB will reveal the true count.

This pattern — normal LDL, elevated ApoB — is particularly common in people with metabolic syndrome, insulin resistance, or elevated triglycerides. Precisely the population that looks "fine" on a standard check-up.

What about ApoA1?

ApoA1 is the primary protein on HDL particles — the "good cholesterol" vehicles that remove cholesterol from arterial walls. The ApoB/ApoA1 ratio gives a single number expressing the balance between atherogenic forces (ApoB) and protective forces (ApoA1). Research shows this ratio outperforms both LDL-C and HDL-C individually as a predictor of cardiovascular mortality.

What Aeonix measures — and why it matters

Every Aeonix panel from Vital Edge upwards includes ApoB, ApoA1, and the ApoB/ApoA1 ratio, alongside Lipoprotein(a) — another underscreened genetic risk factor carried by 20% of the population. Your physician-reviewed report contextualises all of these against your full clinical picture.

Understanding your cardiovascular risk should not require you to know the biochemistry. That is our job. Your job is simply to have the right information.